DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCorporate Action

Sun Pharmaceutical Industries Limited — Alteration Of Capital and Fund Raising-XBRL

NSE 1 hr ago·27 Oct 2026, 6:25 am

Sun Pharmaceutical Industries

Sun Pharmaceutical Industries Limited has informed stock exchanges about the allotment of securities, which is a routine administrative update. This action typically relates to the conversion of warrants or the issuance of fresh shares under existing corporate authorizations. The company has filed the XBRL (eXtensible Business Reporting Language) form to ensure transparency and compliance with regulatory requirements.

For investors, this news is largely procedural and does not signal a major shift in the company's financial strategy. It confirms that the company is moving forward with previously announced capital plans. While it shows the company is executing its roadmap, it does not inherently change the fundamental value of the stock.

Investors should monitor the specific details of the allotment, such as the price at which the new shares were issued and the purpose of the funds raised. This will provide clarity on whether the company is strengthening its balance sheet for expansion or debt repayment. Keep an eye on the company's future disclosures for further context on how these funds will be utilized.